89 related articles for article (PubMed ID: 3621168)
1. Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration.
Ward BG; Mather SJ; Hawkins LR; Crowther ME; Shepherd JH; Granowska M; Britton KE; Slevin ML
Cancer Res; 1987 Sep; 47(17):4719-23. PubMed ID: 3621168
[TBL] [Abstract][Full Text] [Related]
2. Localization of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts.
Ward BG; Wallace K
Cancer Res; 1987 Sep; 47(17):4714-8. PubMed ID: 3621167
[TBL] [Abstract][Full Text] [Related]
3. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration.
Rowlinson G; Snook D; Busza A; Epenetos AA
Cancer Res; 1987 Dec; 47(24 Pt 1):6528-31. PubMed ID: 3677091
[TBL] [Abstract][Full Text] [Related]
4. Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12.
Quadri SM; Malik AB; Tang XZ; Patenia R; Freedman RS; Vriesendorp HM
Cancer Res; 1995 Dec; 55(23 Suppl):5736s-5742s. PubMed ID: 7493338
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal immunoconjugates.
Griffin TW; Collins J; Bokhari F; Stochl M; Brill AB; Ito T; Emond G; Sands H
Cancer Res; 1990 Feb; 50(3 Suppl):1031s-1038s. PubMed ID: 2404580
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
7. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
8. Improved radiolabeled monoclonal antibody uptake by lavage of intraperitoneal carcinomatosis in mice.
Wahl RL; Liebert M
J Nucl Med; 1989 Jan; 30(1):60-5. PubMed ID: 2911043
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.
Buist MR; Kenemans P; den Hollander W; Vermorken JB; Molthoff CJ; Burger CW; Helmerhorst TJ; Baak JP; Roos JC
Cancer Res; 1993 Nov; 53(22):5413-8. PubMed ID: 8221680
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
11. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
12. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.
Deguchi T; Chu TM; Leong SS; Horoszewicz JS; Lee CL
Cancer Res; 1986 Aug; 46(8):3751-5. PubMed ID: 3731053
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
15. Antibody-guided irradiation of malignant ascites in ovarian cancer: a new therapeutic method possessing specificity against cancer cells.
Epenetos AA; Hooker G; Krausz T; Snook D; Bodmer WF; Taylor-Papadimitriou J
Obstet Gynecol; 1986 Sep; 68(3 Suppl):71S-74S. PubMed ID: 3737085
[TBL] [Abstract][Full Text] [Related]
16. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
[TBL] [Abstract][Full Text] [Related]
17. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms.
Epenetos AA; Snook D; Durbin H; Johnson PM; Taylor-Papadimitriou J
Cancer Res; 1986 Jun; 46(6):3183-91. PubMed ID: 3516393
[TBL] [Abstract][Full Text] [Related]
18. Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies.
Malamitsi J; Skarlos D; Fotiou S; Papakostas P; Aravantinos G; Vassilarou D; Taylor-Papadimitriou J; Koutoulidis K; Hooker G; Snook D
J Nucl Med; 1988 Dec; 29(12):1910-5. PubMed ID: 3193206
[TBL] [Abstract][Full Text] [Related]
19. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
